Monday, April 22, 2024
HomeHightechBioTechTEVA Announces FDA Approval For its New Auto-Injector

TEVA Announces FDA Approval For its New Auto-Injector

Teva Pharmaceuticals USA, announced that the Food and Drug Administration (FDA) has approved an auto-injector device for AJOVY® (fremanezumab-vfrm) injection for migraines.

“The approval of the AJOVY auto-injector is another important step forward for Teva and the migraine community,” said Brendan O’Grady, Executive Vice President, North America Commercial, Teva. “AJOVY is the only FDA-approved anti-CGRP that offers the flexibility of quarterly (675 mg) or monthly (225 mg) dosing options, and we are pleased that patients and their healthcare providers will be able to decide if an auto-injector is the right administration option for their needs.”

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments